Researchers at the University of California, Davis developed a novel, cell-based bioassay that detects compounds that impact the estrogen receptor signaling pathway.
The ability of a wide variety of compounds to disrupt normal endocrine homeostasis, and potentially, the physiological and reproductive capacity of an organism, is of great concern.
Researchers at the University of California, Davis developed a stably transfected recombinant human cell line responds to estrogenic chemicals. The cell-based bioassay detects compounds that impact the estrogen receptor signaling pathwayand responds to estrogenic chemicals with the induction of luciferase gene expression in a time-, dose-, and chemical specific manner. The cell line responds to antiestrogenic chemicals with the inhibition of estrogen-dependent gene expression.
Non-exclusive licenses are available for UC's property rights in this cell bioassay and patent rights in the luciferase reporter gene as it is utilized within the cell bioassay.
This cell bioassay system also contains components owned by the Promega Corporation. Licensees can acquire Promega permissions relevant to practicing this invention by executing a contract services agreement directly with Promega. UC can provide interested parties with a draft license agreement as well as a sample of the Promega contract services agreement.
endocrine disruptors, estrogenic chemicals, antiestrogenic chemicals, estrogen receptor signaling pathway